Peapod Lane Capital LLC Makes New $1.10 Million Investment in Nkarta, Inc. (NASDAQ:NKTX)

Peapod Lane Capital LLC bought a new stake in Nkarta, Inc. (NASDAQ:NKTX - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 598,245 shares of the company's stock, valued at approximately $1,101,000. Nkarta makes up approximately 1.2% of Peapod Lane Capital LLC's investment portfolio, making the stock its 29th largest holding. Peapod Lane Capital LLC owned about 0.84% of Nkarta as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Invesco Ltd. bought a new stake in shares of Nkarta during the fourth quarter worth $30,000. Sequoia Financial Advisors LLC acquired a new position in Nkarta during the 4th quarter worth about $31,000. Wealth Enhancement Advisory Services LLC acquired a new position in Nkarta during the 1st quarter worth about $32,000. ProShare Advisors LLC bought a new stake in Nkarta during the 4th quarter worth about $45,000. Finally, Sei Investments Co. bought a new stake in Nkarta during the 4th quarter worth about $57,000. Institutional investors own 80.54% of the company's stock.

Nkarta Trading Up 1.7%

Shares of NKTX traded up $0.03 on Friday, reaching $1.83. 705,608 shares of the company's stock were exchanged, compared to its average volume of 1,029,563. The business has a 50 day moving average price of $1.81 and a two-hundred day moving average price of $1.94. Nkarta, Inc. has a 12 month low of $1.31 and a 12 month high of $8.23. The stock has a market capitalization of $129.86 million, a P/E ratio of -1.21 and a beta of 0.70.

Nkarta (NASDAQ:NKTX - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.43) EPS for the quarter, topping analysts' consensus estimates of ($0.44) by $0.01. Equities research analysts predict that Nkarta, Inc. will post -1.7 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on NKTX. William Blair reaffirmed a "market perform" rating on shares of Nkarta in a research note on Thursday, May 15th. Stifel Nicolaus dropped their price objective on shares of Nkarta from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Thursday, March 27th. Mizuho reduced their price objective on Nkarta from $16.00 to $14.00 and set an "outperform" rating on the stock in a report on Tuesday, June 10th. Needham & Company LLC decreased their price objective on Nkarta from $11.00 to $10.00 and set a "buy" rating on the stock in a research report on Thursday, May 15th. Finally, HC Wainwright reissued a "buy" rating and issued a $18.00 target price on shares of Nkarta in a research note on Thursday, March 27th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $14.33.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.